News
Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...
The global Behcet's Disease market is projected to grow significantly from 2025 to 2035 due to increasing prevalence and improved diagnosis, particul ...
--Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it ...
Data & APIs. Events. Premarket ...
Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.
11d
MedPage Today on MSNThis Drug May Safely Treat Psoriasis Exacerbations From Cancer Therapy"Apremilast remains an attractive therapeutic option, even for ICI-PsA, given that it is not immunosuppressive and therefore ...
Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026 Published. Feb 21, 2025 1:50pm EST. ... Behcets disease and pediatric Crohns disease.
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results